1945950-21-9
1945950-21-9 結(jié)構(gòu)式
基本信息
PDD00017273 >=98% (HPLC)
1-[(1,3-Dimethyl-1H-pyrazol-5-yl)methyl]-1,2,3,4-tetrahydro-N-(1-methylcyclopropyl)-3-[(2-methyl-5-thiazolyl)methyl]-2,4-dioxo-6-quinazolinesulfonamide
6-Quinazolinesulfonamide, 1-[(1,3-dimethyl-1H-pyrazol-5-yl)methyl]-1,2,3,4-tetrahydro-N-(1-methylcyclopropyl)-3-[(2-methyl-5-thiazolyl)methyl]-2,4-dioxo-
物理化學(xué)性質(zhì)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2026/07/06 | S8862 | 1945950-21-9 PDD00017273 | 1945950-21-9 | 5mg | 1777.78元 |
| 2026/07/06 | S8862 | PDD00017273 | 1945950-21-9 | 10mM (1mL in DMSO) | 2104.83元 |
| 2026/07/06 | S8862 | 1945950-21-9 PDD00017273 | 1945950-21-9 | 25mg | 5381.54元 |
常見問題列表
| Target | Value |
|
PARG
(Cell-free assay) | 26 nM |
PDD 00017273 is a potent inhibitor of PARG, with an IC 50 of 26 nM, and a K D of 1.45 nM. PDD 00017273 (10 μM) does not inhibit five common Cytochrome P450 enzymes. PDD 00017273 (30 μM) modestly increasess phosphorylated H2AX (γH2AX) intensity, PDD 00017273 also decreases in NAD/H through PARG inhibition after DNA damage. PDD 00017273 suppresses the ZR-75-1 cells carring BRCA1 and BRCA2 wild type, and exhibits less potent activities against MDA-MB-436 cells carry the 5396 + 1G>A mutation in BRCA1. PDD 00017273 (0.3 μM) inhibits degradation of PAR polymers in MCF7 cells. PDD 00017273 (0.3 μM) also reduces the viability of BRCA1, BRCA2, PALB2, FAM175A, and BARD1 depleted cells. PDD 00017273 stalls replication forks and induces DNA damage that requires homologous recombination (HR) for repair.